Headquartered in Hulsterweg 82, Venlo·Fiscal year ends December·NYSE: QGEN·qiagen.com
About Qiagen
QIAGEN N.V. is a Netherlands-based holding company providing 'Sample to Insight' solutions that let customers extract and analyze molecular information from biological samples. Its offering spans several areas:
- **Sample technologies:** Isolate and process DNA, RNA and proteins from blood, tissue and other materials. Products include automated and manual kits; instruments such as QIAsymphony Connect, QIAsprint Connect and QIAmini; and single-cell kits and services from Parse Biosciences, acquired in late 2025.
- **Diagnostic solutions:** QuantiFERON-TB Gold Plus for latent tuberculosis testing, the QIAstat-Dx syndromic testing system, and Precision Medicine companion diagnostics.
- **PCR / nucleic acid amplification:** Includes the QIAcuity digital PCR platform, qPCR products and OEM products.
- **Genomics / NGS:** Universal NGS panels and QIAGEN Digital Insights bioinformatics, including clinical bioinformatics, IPA and Genoox.
Consumables and related revenues account for about 91% of sales. QIAGEN serves more than 500,000 customers in Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). It employed about 5,400 people across more than 35 locations as of September 30, 2026. In October 2026, QIAGEN agreed to be acquired by the EQT XI fund through an all-cash public takeover offer of €46.50 per share, expected to close in mid-2027. Updated
With the Fed rate decision dropping at 2:30 PM and Alphabet and Microsoft reporting before the bell, Wednesday's analyst calls on Enphase, Spotify, Whirlpool, and a newly public Rangers franchise land at…
Pre-Market Stock Futures: Futures are lower after a huge mid-week follow-through rally fueled by spectacular earnings and forward guidance from Space Exploration and Technologies (NASDAQ: SPCX | SPCX Price Prediction). Elon Musk’s…
Pre-Market Stock Futures: Futures are trading lower after a mixed start to trading on Monday, following the holiday-shortened week due to the Juneteenth Federal holiday. We may start to see some end-of-the-quarter…
Pre-Market Stock Futures: The futures are trading mixed this morning, after what started as another week of the same old song and dance yesterday, before stocks turned around before noon, and it…
Wednesday's top analyst upgrades and downgrades included CVS Health, DataDog, Endeavor, Enphase Energy, Extreme Networks, GitLab, Nvidia, RTX, Splunk and United Parcel Service.
The top analyst upgrades, downgrades and initiations seen on Tuesday included AFL, Agilent, Allergan, Barrick Gold, Cognex, Hilton, Lloyds, MetLife, Slack and Wingstop.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK Partners and Sunrun.
Thursday's top analyst upgrades, downgrades and initiations include AMAG Pharmaceuticals, Devon Energy, eBay, Freshpet, Range Resources, Raytheon, SeaWorld and Zynga.
A new report from Cowen makes the case that a blood test that detects evidence of cancer in the circulation could soon replace the older more traditional biopsy methods.
U.S. equity markets opened slightly higher this morning following the report on U.S. jobless numbers (more coverage here). In Europe, the only data out today showed that U.K. retail sales fell 0.7%,…
Jon OggWhile investors generally see analysts issuing Buy ratings, it is always interesting to see what happens when Wall St. analysts give stocks to sell or when they have very cautious comments…
Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector performed very well…
QIAGEN N.V. is a Netherlands-based holding company providing 'Sample to Insight' solutions that let customers extract and analyze molecular information from biological samples. Its offering spans several areas: - **Sample technologies:** Isolate and process DNA, RNA and proteins from blood, tissue and other materials.
What is the QGEN stock price target?
24/7 Wall St.'s 12-month price target for QGEN is $53.22, rated Buy. The Wall Street consensus target is $49.77. QGEN price prediction →